SECsense Logo

Abivax SA's January 2025 Form 6-K Report - Key Developments & Insights

$ABVX
Form 6-K
Filed on: 2025-01-10
Source
Abivax SA's January 2025 Form 6-K Report - Key Developments & Insights

Here’s a summary of the key information extracted from the provided section of the financial report (Form 6-K) for Abivax SA:

  1. Filing Details:
  • Type: Form 6-K
  • Commission File Number: 001-41842
  • Date of Report: January 10, 2025
  • Report Period: January 2025
  1. Company Information:
  • Name: Abivax SA
  • Address: 7-11 boulevard Haussmann, 75009 Paris, France
  • Contact: +33 (0) 1 53 83 08 41
  1. Press Release:
  • The company issued a press release on January 9, 2025. The details of the press release can be found in Exhibit 99.1 attached to this report.
  1. Incorporation by Reference:
  • The report, along with Exhibit 99.1, is incorporated by reference into the company's registration statement on Form F-3 (File No. 333-283336).
  1. Executive Signature:
  • The report is signed by Marc de Garidel, Chief Executive Officer of Abivax SA.

Insights:

  • This filing is part of Abivax SA's compliance with the Securities Exchange Act of 1934, specifically targeted towards foreign private issuers.
  • The issuance of a press release shortly before this filing suggests that the company may be announcing significant developments or updates relevant to stakeholders.
  • The incorporation of the report into the company's registration statement indicates ongoing regulatory obligations and the company's commitment to transparency.

This summary highlights the essential aspects of the financial report and provides a basis for further analysis of Abivax SA's current status and any key developments that may affect its operations or stock performance.